Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
← catalyst calendarSponsored by Karyopharm Therapeutics Inc (industry) · KPTI — their whole pipeline →.
Phase
Phase 1/2
Status
Withdrawn
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
0actual
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-18 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions
- Drug: Selinexor — also filed as KPT-330
- Drug: Rituximab
- Drug: Bendamustine
- Drug: Polatuzumab Vedotin
- Drug: Ibrutinib
- Drug: Lenalidomide
- Drug: Tafasitamab
- Drug: Venetoclax
- Drug: Gemcitabine
- Drug: Oxaliplatin
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Maximum Tolerated Dose (MTD)
measured Within the first cycle (maximum 28 days) of treatment
Phase 1: Recommended Phase 2 Dose (RP2D)
measured Up to 6 cycles (up to 6 months) of treatment
Phase 2: Overall Response Rate (ORR) per the Lugano Classification 2014
measured Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months)
Permalink · KPTI's whole pipeline · Catalyst calendar · Every registered study · What changed